Bausch Health Cos

Bausch Health Cos, a Pharmaceutical Preparation Manufacturing company headquartered in CA, reported its 2023 Scope 1 emissions as 49,906,000 kg CO2e. Market-based Scope 2 emissions for the same year were 51,990,000 kg CO2e, while location-based Scope 2 emissions were 65,518,000 kg CO2e. The company also reported 27,107,000 kg CO2e for Scope 3 emissions from waste generated in operations in 2023.

For 2022, Bausch Health Cos's Scope 1 emissions were 46,686,000 kg CO2e. Market-based Scope 2 emissions stood at 50,513,000 kg CO2e, and location-based Scope 2 emissions were 64,814,000 kg CO2e. Scope 3 emissions from waste generated in operations for 2022 were 19,260,000 kg CO2e.

Bausch Health Cos has near-term Science Based Targets initiative (SBTi) commitments to reduce Scope 1 and Scope 2 greenhouse gas emissions by 42% by 2030, using a 2020 base year. Additionally, the company commits to measure and reduce its Scope 3 emissions. These targets were approved using a streamlined validation route for small and medium-sized enterprises (SMEs).